Inventiva stock has recently seen no change in its fair value target, which remains steady at $7.95 per share. However, updated market narratives highlight a slight increase in the discount rate and ...
Liver cancer is a growing global concern, affecting non-drinkers due to conditions like MASLD and MASH linked to lifestyle ...
Viking Therapeutics Inc. (NASDAQ: VKTX) stock is soaring after the company delivered its third-quarter earnings report. The ...
The nonalcoholic steatohepatitis market is poised for significant expansion with the approval of REZDIFFRA and a robust clinical development pipeline. Key companies shaping the future of NASH ...
Once almost exclusively seen in older adults, fatty liver disease, which can be fatal if untreated, is now one of the world’s ...
For years, MASH was where drug development dreams went to die. | After Rezdiffra’s approval and Wegovy’s label expansion, ...
An international collaborative study has identified the E2F2 protein as a potential new therapeutic target to prevent ...
MariTide is now progressing into phase 3 trials, with a focus on its long-term safety and efficacy. Amgen expects to apply ...
Akero Therapeutics (($AKRO)) announced an update on their ongoing clinical study. Study Overview: Akero Therapeutics is conducting a Phase 3 study ...
Fatty liver disease, a common liver condition, can be managed and reversed through regular exercise. Physical activity ...
TipRanks on MSN
GSK’s New Phase 3 Study on Efimosfermin Alfa: A Potential Game-Changer for Liver Disease Treatment
GlaxoSmithKline (($GSK)) announced an update on their ongoing clinical study. GlaxoSmithKline (GSK) has announced a new clinical study titled ‘A ...
Two newly approved medications expand options beyond lifestyle modifications for metabolic dysfunction-associated steatotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback